Biohaven Ltd. (BHVN) intrinsic value & 10-year financials
Biohaven Ltd. (BHVN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.78
- Market cap
- $1.2B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -276.7%
- Free cash flow (FY2025)
- -$610.2M
BHVN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$738.8M | -$6.86 | -$610.2M | — | -680.2% |
| FY2024 | — | -$846.4M | -$9.28 | -$586.5M | — | -313.7% |
| FY2023 | — | -$408.2M | -$5.73 | -$334.8M | — | -152.1% |
| FY2022 | — | -$570.3M | -$12.75 | -$303.8M | — | -348.5% |
| FY2021 | — | -$213.8M | -$5.43 | -$146.8M | — | 567.6% |
| FY2020 | — | -$118.7M | -$3.01 | -$77.1M | — | -733.3% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Biohaven Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Biohaven Ltd. has historically struggled to out-earn its cost of capital, averaging just -2.8% ROIC.
Biohaven Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Biohaven Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.